Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2002 17
2003 11
2004 9
2005 14
2006 19
2007 15
2008 24
2009 29
2010 20
2011 19
2012 23
2013 26
2014 13
2015 15
2016 13
2017 10
2018 15
2019 5
2020 15
2021 17
2022 14
2023 28
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

321 results

Results by year

Filters applied: . Clear all
Page 1
The Costs of Anonymization: Case Study Using Clinical Data.
Pilgram L, Meurers T, Malin B, Schaeffner E, Eckardt KU, Prasser F; GCKD Investigators. Pilgram L, et al. J Med Internet Res. 2024 Apr 24;26:e49445. doi: 10.2196/49445. J Med Internet Res. 2024. PMID: 38657232 Free article.
Fixed low dose versus concentration-controlled initial tacrolimus dosing with reduced target levels in the course after kidney transplantation: results from a prospective randomized controlled non-inferiority trial (Slow & Low study).
Stumpf J, Budde K, Witzke O, Sommerer C, Vogel T, Schenker P, Woitas RP, Opgenoorth M, Trips E, Schrezenmeier E, Hugo C; German S&L Study. Stumpf J, et al. EClinicalMedicine. 2023 Dec 22;67:102381. doi: 10.1016/j.eclinm.2023.102381. eCollection 2024 Jan. EClinicalMedicine. 2023. PMID: 38152417 Free PMC article.
Prospective Cohort Study of Soluble Urokinase Plasminogen Activation Receptor and Cardiovascular Events in Patients With CKD.
Sommerer C, Müller-Krebs S, Nadal J, Schultheiss UT, Friedrich N, Nauck M, Schmid M, Nußhag C, Reiser J, Eckardt KU, Zeier M, Hayek SS; German Chronic Kidney Disease Investigators. Sommerer C, et al. Kidney Int Rep. 2023 Sep 9;8(11):2265-2275. doi: 10.1016/j.ekir.2023.08.038. eCollection 2023 Nov. Kidney Int Rep. 2023. PMID: 38025216 Free PMC article.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Copeptin, Natriuretic Peptides, and Cardiovascular Outcomes in Patients With CKD: The German Chronic Kidney Disease (GCKD) Study.
Schneider MP, Schmid M, Nadal J, Krane V, Saritas T, Busch M, Schultheiss UT, Meiselbach H, Friedrich N, Nauck M, Floege J, Kronenberg F, Wanner C, Eckardt KU; GCKD study investigators. Schneider MP, et al. Kidney Med. 2023 Sep 17;5(11):100725. doi: 10.1016/j.xkme.2023.100725. eCollection 2023 Nov. Kidney Med. 2023. PMID: 37915964 Free PMC article.
Cardiovascular risk due to diabetes mellitus in patients with chronic kidney disease-prospective data from the German Chronic Kidney Disease cohort.
Ruhe J, Nadal J, Bärthlein B, Meiselbach H, Schultheiss UT, Kotsis F, Stockmann H, Krane V, Sommerer C, Löffler I, Saritas T, Kielstein JT, Sitter T, Schneider MP, Schmid M, Wanner C, Eckardt KU, Wolf G, Busch M. Ruhe J, et al. Among authors: wolf g. Clin Kidney J. 2023 Sep 1;16(11):2032-2040. doi: 10.1093/ckj/sfad194. eCollection 2023 Nov. Clin Kidney J. 2023. PMID: 37915914 Free PMC article.
Association of mineral and bone biomarkers with adverse cardiovascular outcomes and mortality in the German Chronic Kidney Disease (GCKD) cohort.
Reimer KC, Nadal J, Meiselbach H, Schmid M, Schultheiss UT, Kotsis F, Stockmann H, Friedrich N, Nauck M, Krane V, Eckardt KU, Schneider MP, Kramann R, Floege J, Saritas T; GCKD study investigators. Reimer KC, et al. Bone Res. 2023 Oct 20;11(1):52. doi: 10.1038/s41413-023-00291-8. Bone Res. 2023. PMID: 37857629 Free PMC article.
321 results